Multiple fraction-per-day radiotherapy for patients with brain stem tumors

Mary E. Hebert, Edward C. Halperin, W. Jerry Oakes, Orest Boyko

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Brain stem tumors are among the most resistant brain tumors to therapy. The majority progress within 18 months of diagnosis and treatment. Multiple-fraction-per-day (MFD) radiotherapy would theoretically allow higher total doses of radiotherapy to be delivered in order to improve local tumor control without increasing neurotoxicity secondary to treatment. Seventeen patients with brain stem tumors were evaluated and treated at Duke University Medical Center (DUMC) from 1985 to 1991 with a MFD regimen. Six patients were accrued to Pediatric Oncology Group (POG) Protocol 8495 and were not included in this analysis, leaving eleven patients for review. Local fields were treated with fraction sizes of 110 or 117 cGy twice daily. There were 3 patients who received a total of 60.5-68.2 Gy and 8 who received 70.2-71.5 Gy. Initial and follow-up CT and/or MRI studies were available for review on all but one patient. All patients had progression of disease and have died. Median time to tumor progression was 5.8 months. Median overall survival was 11.2 months. There was no significant influence upon time to tumor progression or survival by total radiation dose received. Patients were classified by imaging group per the criteria of Stroink et al. based on review of their pre-treatment CT or MRI scans. One patient had no initial films available, 2 were in Group II (no contrast was given to separate A or B), 3 in IIA, 4 in IIB, and 1 in III. Autopsy in 3 patients failed to demonstrate histologic evidence of injury attributable to radiotherapy. The results of this study fail to demonstrate a positive impact of MFD radiotherapy on the outcome of children with unresectable brain stem tumors.

Original languageEnglish (US)
Pages (from-to)131-138
Number of pages8
JournalJournal of Neuro-Oncology
Volume17
Issue number2
DOIs
StatePublished - Jun 1993
Externally publishedYes

Fingerprint

Brain Stem Neoplasms
Radiotherapy
Neoplasms
Survival
Therapeutics
Brain Neoplasms
Disease Progression
Autopsy
Magnetic Resonance Imaging
Radiation
Pediatrics

Keywords

  • (treatment, radiotherapy)
  • brain neoplasms
  • brain stem tumors

ASJC Scopus subject areas

  • Neuroscience(all)
  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Multiple fraction-per-day radiotherapy for patients with brain stem tumors. / Hebert, Mary E.; Halperin, Edward C.; Oakes, W. Jerry; Boyko, Orest.

In: Journal of Neuro-Oncology, Vol. 17, No. 2, 06.1993, p. 131-138.

Research output: Contribution to journalArticle

Hebert, Mary E. ; Halperin, Edward C. ; Oakes, W. Jerry ; Boyko, Orest. / Multiple fraction-per-day radiotherapy for patients with brain stem tumors. In: Journal of Neuro-Oncology. 1993 ; Vol. 17, No. 2. pp. 131-138.
@article{ef4057c1e14b45c9a48273ebc2b7b28a,
title = "Multiple fraction-per-day radiotherapy for patients with brain stem tumors",
abstract = "Brain stem tumors are among the most resistant brain tumors to therapy. The majority progress within 18 months of diagnosis and treatment. Multiple-fraction-per-day (MFD) radiotherapy would theoretically allow higher total doses of radiotherapy to be delivered in order to improve local tumor control without increasing neurotoxicity secondary to treatment. Seventeen patients with brain stem tumors were evaluated and treated at Duke University Medical Center (DUMC) from 1985 to 1991 with a MFD regimen. Six patients were accrued to Pediatric Oncology Group (POG) Protocol 8495 and were not included in this analysis, leaving eleven patients for review. Local fields were treated with fraction sizes of 110 or 117 cGy twice daily. There were 3 patients who received a total of 60.5-68.2 Gy and 8 who received 70.2-71.5 Gy. Initial and follow-up CT and/or MRI studies were available for review on all but one patient. All patients had progression of disease and have died. Median time to tumor progression was 5.8 months. Median overall survival was 11.2 months. There was no significant influence upon time to tumor progression or survival by total radiation dose received. Patients were classified by imaging group per the criteria of Stroink et al. based on review of their pre-treatment CT or MRI scans. One patient had no initial films available, 2 were in Group II (no contrast was given to separate A or B), 3 in IIA, 4 in IIB, and 1 in III. Autopsy in 3 patients failed to demonstrate histologic evidence of injury attributable to radiotherapy. The results of this study fail to demonstrate a positive impact of MFD radiotherapy on the outcome of children with unresectable brain stem tumors.",
keywords = "(treatment, radiotherapy), brain neoplasms, brain stem tumors",
author = "Hebert, {Mary E.} and Halperin, {Edward C.} and Oakes, {W. Jerry} and Orest Boyko",
year = "1993",
month = "6",
doi = "10.1007/BF01050215",
language = "English (US)",
volume = "17",
pages = "131--138",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Multiple fraction-per-day radiotherapy for patients with brain stem tumors

AU - Hebert, Mary E.

AU - Halperin, Edward C.

AU - Oakes, W. Jerry

AU - Boyko, Orest

PY - 1993/6

Y1 - 1993/6

N2 - Brain stem tumors are among the most resistant brain tumors to therapy. The majority progress within 18 months of diagnosis and treatment. Multiple-fraction-per-day (MFD) radiotherapy would theoretically allow higher total doses of radiotherapy to be delivered in order to improve local tumor control without increasing neurotoxicity secondary to treatment. Seventeen patients with brain stem tumors were evaluated and treated at Duke University Medical Center (DUMC) from 1985 to 1991 with a MFD regimen. Six patients were accrued to Pediatric Oncology Group (POG) Protocol 8495 and were not included in this analysis, leaving eleven patients for review. Local fields were treated with fraction sizes of 110 or 117 cGy twice daily. There were 3 patients who received a total of 60.5-68.2 Gy and 8 who received 70.2-71.5 Gy. Initial and follow-up CT and/or MRI studies were available for review on all but one patient. All patients had progression of disease and have died. Median time to tumor progression was 5.8 months. Median overall survival was 11.2 months. There was no significant influence upon time to tumor progression or survival by total radiation dose received. Patients were classified by imaging group per the criteria of Stroink et al. based on review of their pre-treatment CT or MRI scans. One patient had no initial films available, 2 were in Group II (no contrast was given to separate A or B), 3 in IIA, 4 in IIB, and 1 in III. Autopsy in 3 patients failed to demonstrate histologic evidence of injury attributable to radiotherapy. The results of this study fail to demonstrate a positive impact of MFD radiotherapy on the outcome of children with unresectable brain stem tumors.

AB - Brain stem tumors are among the most resistant brain tumors to therapy. The majority progress within 18 months of diagnosis and treatment. Multiple-fraction-per-day (MFD) radiotherapy would theoretically allow higher total doses of radiotherapy to be delivered in order to improve local tumor control without increasing neurotoxicity secondary to treatment. Seventeen patients with brain stem tumors were evaluated and treated at Duke University Medical Center (DUMC) from 1985 to 1991 with a MFD regimen. Six patients were accrued to Pediatric Oncology Group (POG) Protocol 8495 and were not included in this analysis, leaving eleven patients for review. Local fields were treated with fraction sizes of 110 or 117 cGy twice daily. There were 3 patients who received a total of 60.5-68.2 Gy and 8 who received 70.2-71.5 Gy. Initial and follow-up CT and/or MRI studies were available for review on all but one patient. All patients had progression of disease and have died. Median time to tumor progression was 5.8 months. Median overall survival was 11.2 months. There was no significant influence upon time to tumor progression or survival by total radiation dose received. Patients were classified by imaging group per the criteria of Stroink et al. based on review of their pre-treatment CT or MRI scans. One patient had no initial films available, 2 were in Group II (no contrast was given to separate A or B), 3 in IIA, 4 in IIB, and 1 in III. Autopsy in 3 patients failed to demonstrate histologic evidence of injury attributable to radiotherapy. The results of this study fail to demonstrate a positive impact of MFD radiotherapy on the outcome of children with unresectable brain stem tumors.

KW - (treatment, radiotherapy)

KW - brain neoplasms

KW - brain stem tumors

UR - http://www.scopus.com/inward/record.url?scp=0027764552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027764552&partnerID=8YFLogxK

U2 - 10.1007/BF01050215

DO - 10.1007/BF01050215

M3 - Article

VL - 17

SP - 131

EP - 138

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -